Paratek Pharmaceuticals Presenting New Data from NUZYRA and Investigator-Initiated Research Programs at ASM Microbe 2023
PRTKDelisted Stock | USD 2.18 0.00 0.00% |
About 56% of Paratek Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Paratek Pharmaceuticals suggests that many traders are alarmed regarding Paratek Pharmaceuticals' prospects. Paratek Pharmaceuticals' investing sentiment shows overall attitude of investors towards Paratek Pharmaceuticals.
Paratek |
BOSTON, June 12, 2023 Paratek Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that new data from studies with NUZYRA will be presented at ASM Microbe 2023 conference. The hybrid conference will be held June 15-19 at the George R
Read at finance.yahoo.com
Paratek Pharmaceuticals Fundamental Analysis
We analyze Paratek Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Paratek Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Paratek Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Paratek Pharmaceuticals is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Paratek Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Paratek Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Paratek Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Paratek Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Paratek Pharmaceuticals Related Equities
LYRA | Lyra Therapeutics | 10.53 | ||||
APTO | Aptose Biosciences | 5.56 | ||||
EQ | Equillium | 1.41 | ||||
CRVS | Corvus Pharmaceuticals | 0.36 | ||||
HOOK | Hookipa Pharma | 1.16 | ||||
JSPR | Jasper Therapeutics | 1.46 | ||||
IMMP | Immutep | 1.46 | ||||
ADAP | Adaptimmune Therapeutics | 2.78 | ||||
LPTX | Leap Therapeutics | 3.79 | ||||
AFMD | Affimed NV | 10.43 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |